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Abstract
Background Retinal S-antigen (S-Ag) is a most character-
ized autoantigen of autoimmune uveitis. The recognized
immunodominant epitope of human S-Ag in patients with
uveitis has not been identified. In this study, we selected
certain patients with active uveitis to map the Th1 cell
epitope spectrum of human S-Ag in Behcet’s disease(BD).
Methods Blood samples were taken from eight active BD
patients who showed an immune response to 40 mixed
overlapping peptides spanning the entire sequence of
human S-Ag. Peripheral blood mononuclear cells were
isolated and stimulated with single S-Ag peptide at 5 μg/ml
or 20 μg/ml. Single-cell immune responses were measured
by IFN-γ ELIspot assay.
Results BD patients heterogeneously responded to the S-
Ag peptides at two concentrations. In general, the responses
to 5 μg/ml peptides were slightly stronger than those to
20 μg/ml peptides, while the maximum SFC frequency to
single peptide at the two concentrations was similar.
Several peptides including P31, P35 and P40 induced a
prominent response, with the frequency of S-Ag specific
cells being about 0.007%. Significant reactivity pattern shift
was noted in patients with different disease courses.
Conclusions Certain active BD patients have S-Ag specific
Th1 cells with a low frequency. The S-Ag epitope
specificity between patients is highly heterogeneous, and
varies with the uveitis course.
Keywords Behcet’s disease . Epitope mapping .
Retinal S antigen . Uveitis
Introduction
Uveitis is a group of clinically heterogeneous intraocular
inflammatory diseases often leading to severe impairment
of visual acuity. It has been presumed to be mediated by
autoreactive CD4+ T cells recognizing specific retinal
antigens [1]. The most persuasive evidence stems from
the observation that autoantigens such as retinal S-antigen
(S-Ag) can induce experimental autoimmune uveitis
(EAU), similar to human uveitis clinically and histologi-
cally in susceptible animals [2]. Furthermore, oral admin-
istration of bovine S-Ag or immunizing rats with human
S-Ag-Ig fusion protein can induce immune tolerance,
thereby preventing uveitis [3, 4]. Usually a typical immune
response against a self protein is focused on one or two
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epitopes within that protein [5]. Immunodominant epitopes
of human S-Ag have been investigated in a variety of
uveitis entities through lymphocyte proliferation assay
[6–8]. However, no peptide was found to induce a
predominant immune response in all or most responders.
Behcet’s disease (BD) is one of the common uveitis
entities in China [9], and lymphocytes in certain BD
patients proliferated upon S-Ag stimulation [10]. Enzyme-
linked immunospot assay (ELIspot) has been shown to be
the most specific and sensitive technique for assessing low-
frequency antigen specific T cells. In this study, we adopted
the ELIspot assay to map the T cell epitope peptide




Forty peptides spanning the entire length of human S-Ag
sequence (pubmed locus P10523) were synthesized by
conventional solid-phase chemistry and purified to at least
95% purity (Sangon Biological Engineering Technology &
Services Company, Shanghai, China). Each peptide deter-
minant measured 20 amino acids (aa) in length and
overlapped the neighboring sequence by 10 aa, except for
the last one, which measured 15 aa. The exact sequence and
naming of the overlapping peptides are shown in Fig. 1.
Subjects
Eight male BD patients with active uveitis with an average
age of 31 years (ranged from 20 to 43 years) were included
in this study. The patients met the diagnostic criteria
established by the International Behcet’s Disease Study
Group [11]. All patients showed cellular responses to mixed
S-Ag peptides and were positive for human leucocyte
antigen (HLA)-B51 in our previous study [12]. Their mean
durations of uveitis were 27 months (ranging from 13 to
35 months). All the patients relapsed into panuveitis,
manifested by dust-like keratic precipitates, flare and cells
in the anterior chamber, hypopyon, vitreous cells and retinal
vasculitis as disclosed by fluorescein angiography. Five
patients were receiving low-dose prednisone (20 mg/day or
less) therapy, and the remaining three BD patients had no
systemic treatment at the time of blood sampling. No
healthy donors showed positive cellular responses to mixed
S-Ag peptide in our previous study; therefore we did not
use normal individuals as a control. All procedures
followed the tenets of the Declaration of Helsinki and were
approved by the Zhongshan Ophthalmic Center Ethics
Committee, and blood samples were obtained from the
patients after they had given their written informed consent.
IFN-γ ELIspot
Peripheral venous blood (18 ml or 34 ml) was drawn in a
heparinized tube, and peripheral blood mononuclear cells
(PBMCs) were isolated immediately by Ficoll–Hypaque
density gradient centrifugation (Pharmacia Biotech, Shang-
hai, China). The ELIspot assay kit for IFN-γ was purchased
from BD Pharmingen (BD Biosciences, San Diego, CA,
USA) and utilised according to the manufacturer’s instruc-
tions. Briefly, 96-well nitrocellulose plates (Millipore) were
coated with 5 μg/ml anti-human ‡IFN-γ capture antibody
at 4°C overnight. A total of 2×105 fresh PBMCs were
added to microwells in duplicate, and incubated with 40
single S-Ag synthetic peptides (5 μg/ml or 20 μg/ml for
each peptide) for 20 h in the presence of 1 μg/ml
costimulatory anti-CD28 (BD Pharmingen, clone CD28.2)
monoclonal antibody (mAb). PBMCs cultured without
peptides acted as negative controls. PBMCs stimulated
with 10 ng/ml anti-CD3 (BD Pharmingen, clone HIT3a)
plus 1 μg/ml anti-CD28 mAbs were used as positive
controls. Two μg/ml biotinylated anti-human IFN-γ,
streptavidin–HRP at 1:100 dilution and AEC were used as
detection antibody, biotinylated detection antibody and
substrate reagent respectively. The spots were counted
automatically using ImmunoSpot Image Analyzer (Cellular
Technology Limited, Cleveland, OH, USA). Digitized
images were analyzed for the presence of areas in which
color density exceeds background by an amount set on the
basis of the comparison of experimental wells and negative
control wells. A spot called spot-forming cell (SFC)
represented an IFN-γ-producing cell. The number of spots
in negative control wells was less than two.
Fig. 1 The sequence of 40 overlapping peptides that spanned the
entire amino acid sequence of human S-Ag
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Statistical analysis
Data are expressed as mean ± SD. Statistical analysis was
performed using the Mann-Whitney U test and the linear
mixed-effects model fit by the maximum likelihood method
by statistical software SAS 9.1 (SAS Inc., Cary, NC, USA).
A P value of less than 0.05 was considered statistically
significant.
Results
Assessment of cellular immune response to S-Ag peptides
by IFN-γ ELIspot
Our preliminary study found that 5 μg/ml of mixed S-Ag
peptides was an optimal concentration for ELIspot assay.
Therefore, that concentration was used in this study. Since
earlier studies showed that 20 μg/ml of S-Ag peptides
induced an optimal lymphocyte proliferative responses in
patients with uveitis[7, 8], we simultaneously adopted this
concentration for ELIspot assay in five out of eight patients.
The results revealed highly heterogeneous responses
against individual peptides at either concentration in all
the patients (Fig. 2a,b). In general, each patient responded
to more than one of the peptides in the panel, and the
reactivity of the same peptide varied between patients. Both
concentrations of antigens induced a similar SFC frequency
with 0.007% (14/2×105) vs 0.006% (12/2×105) for the
strongest reactive peptide at 5 μg/ml vs 20 μg/ml (Fig. 2c).
The maximum frequency of T cell response against single
peptide at the two concentrations was the same as that
against mixed peptides at 5 μg/ml (0.0065% [13/2×105]).
However, generally speaking, the responses to 5 μg/ml of
40 single peptides were stronger than that to 20 μg/ml of
peptides (Fig. 2d). Additionally, the dominant sites of S-Ag
at 5 μg/ml obviously localized at the C-terminal region
of this protein, whereas that at 20 μg/ml was noted at
the N-terminal.
When PBMCs were stimulated with polyclonal anti-
CD3 plus anti-CD28, a high frequency of IFN-γ-
secreting cells (0.1525% [305/2×105]) was observed in
all patients. It was much higher than that induced by S-Ag
peptide (P<0.01, P<0.01) (Fig. 2c).
Identification of immunodominant T cell epitopes of S-Ag
In view of the highly heterogeneous reactivity spectrum
in different individuals, we applied the linear mixed-
effects model fit by the maximum likelihood method
with the number of cases as the random effect, to
analyze the difference in SFC frequency between 40
Fig. 2 Mapping of Th1 cell responses to individual S-Ag peptides.
PBMCs were cultured with mixed S-Ag peptides at 5 μg/ml, single
peptides at 5 or 20 μg/ml and anti-CD3 respectively. IFN-γ-producing
cells were determined by ELIspot and expressed as SFC. Data are
expressed as means ± SD and bars indicate mean values. A
statistically significant difference was set at P<0.05 (#), P<0.01 (*),
ns: not significant. a Shows the Th1 cell response spectrum of S-Ag
peptides at 5 μg/ml (n=8). The SFC frequency was analyzed by the
linear mixed-effects model fit by the maximum likelihood method,
and the dominant responses were marked. b Shows the Th1 cell
response spectrum of S-Ag peptides at 20 μg/ml (n=5). c The SFC
frequency for stimulation with mixed peptides, strongest single
peptide (5 and 20 μg/ml respectively) and anti-CD3 were compared.
Statistical analysis was performed using Mann-Whitney U test. d The
SFC frequency of the single peptides screening at the two concen-
trations was compared (n=5)
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peptides at 5 μg/ml. The results showed that the responses
to P31 (P=0.013), P35 (P=0.015) and P40 (P=0.001) were
significantly stronger than to other peptides.
Shift in peptides recognition in patients with different
disease course
To investigate whether the S-Ag peptides response spec-
trum was influenced by the disease course of uveitis, we
divided the eight cases into two groups according to their
different duration of uveitis. Group one included three
patients with a uveitis course of no more than 2 years; the
other included five patients having uveitis for more than
2 years. Their SFC frequency of response to the 40 peptides
at 5 μg/ml was compared by linear mixed-effects model fit
by the maximum likelihood method. In general, the
response in patients with a disease course less than 2 years
was stronger than that in patients with a disease course of
more than 2 years. The patients with uveïtis duration less
than 2 years dominantly recognized P40 (P=0.001). When
the uveitis course extended to around 3 years in BD
patients, the dominant response to S-Ag peptides varied to
P27 (P=0.009), P29 (P=0.049), P30 (P=0.030), and P31
(P=0.001) (Fig. 3).
Discussion
In this study, we applied the ELIspot assay to map the S-Ag
Th1 cell epitopes response in a series of BD patients with
similar disease characteristics. The results show that the
peptides induced a low frequency of S-Ag specific Th1
cells, and that the T cell response against peptides is highly
heterogeneous in different individuals. Several dominant
peptides including P31, P35 and P40 were observed
statistically in certain patients. The reactivity pattern to
the peptides varied in patients with different disease
duration.
It has been shown that a greatly heterogeneous T-cell
proliferative response spectrum against S-Ag peptides in
uveitis may be attributed to variation in disease entities and
different stages of disease activity of the examined patients
[6–8]. To exclude the above factors in the antigenic peptide
mapping, we chose BD patients with a similar intensity of
uveitis at the time of blood sampling. In view of the fact
that an efficiently processed specific antigen epitope is
restricted by major histocompatibility complex (MHC) on
the surface of an antigen-presenting cell, and that BD
was associated with HLA-B51 in many ethnic groups
[13, 14], we chose the patients expressing HLA-B51 as
subjects in this study. The result showed that these patients
also heterogeneously recognized the S-Ag peptides, sug-
gesting that the S-Ag epitopes may be not associated with
HLA-B51.
Although lymphocyte proliferation assay is a classic
technique to assess cellular immunity, a non-proliferation
measurement to characterize low-frequency antigen-specific
T cell in autoimmune disease (AID) is needed to avoid
overall clonal expansion and promiscuous T cell popula-
tions. The cytokine-specific ELIspot assay is able to display
one reactive cell among one million T cells at the single cell
level [15], and has been extensively applied to research on
autoimmunity in various AID [16, 17]. Because an IFN-γ
mediated Th1 response has been implicated in the devel-
opment of BD [18], we adopted the IFN-γ ELIspot assay to
map the S-Ag Th1 cell epitopes in BD patients.
To identify the immunodominant epitope of human S-Ag
in uveitis, we used 40 overlapping peptides that are
identical to the peptides used in earlier studies in uveitis
patients [6–8]. The immune responses in those studies were
Fig. 3 Shift in S-Ag peptide recognition in patients with different
disease courses. According to the different duration of uveitis, the
subjects were divided into two groups. Group 1 included patients with
a uveitis course of less than 2 years (n=3), group 2 included patients
with a disease duration of more than 2 years (n=5). The SFC
frequency was analyzed using the linear mixed-effects model fit by the
maximum likelihood method
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tested by lymphocyte proliferation assay. If a stimulation
index (SI) ≥2 was considered a positive reaction, almost all
of the S-Ag peptides except for P12 induced a positive
response in different patients with various uveitis entities
[6–8]. In BD patients, as shown in Table 2 of their paper, de
Smet et al. [6] found that the responses to P18 and P40
were significantly higher than those in healthy controls.
Similar peptides have been tested in the EAU model for
their pathogenicity [19]. Ten peptides induced visible
inflammation in the eye, and the most pathogenic sequen-
ces were P19, P35 and P36. Our ELIspot assay similarly
showed a heterogeneous reactivity pattern in BD patients.
The dominant peptide P35 coincided with the major
pathogenic epitope in rat, and the prominent P40 was
identical with the result of proliferation assays in BD.
Therefore, P40 may be the most potential BD-associated S-
Ag epitope peptide, and the immunodominant epitopes of
S-Ag in uveitis may nest in the amino acid sequence of P35
and P40. However, it needs to be verified using smaller
synthetic peptides in more uveitis patients.
The ELIspot assay quantified a low frequency of 0.007%
(14/2×105) of S-Ag specific T cells in the peripheral
circulation of BD patients with active uveitis. It was
notably lower than that seen in animals with EAU [20].
The low frequency of SFC observed in our study is
consistent with the weak proliferative response to S-Ag in
uveitis patients [6–8].
Epitope spreading has been considered to be one of the
mechanisms contributing to relapses in AID [21]. Deeg et
al. [22] found that the epitopes recognized by uveitic horses
could spread to different peptides of S-Ag or to the peptides
derived from other uveitogenic autoantigens during the
uveitic episodes. A shift in the specific proliferative
response of S-Ag peptides was observed in two BD patients
by testing the responses on two separate occasions[6].
Interestingly, we found that the BD patients with shorter
uveitis course reacted more strongly to S-Ag and inten-
sively responded to one dominant peptide, while those with
a long disease course responded to others. This phenome-
non seem to suggest that autoantigenic epitope spreading
may be present in human uveitis.
Our patients showed a stronger response to low-
concentration peptides than high-concentration ones, which
was different from de Smet’s finding [6]. In addition, the
dominant responses induces by the two concentration
antigens were not coincident. The discrepancy between
the two concentration peptides may be due to different
antigen doses affecting the development of T-cell repertoire
to a given antigen in vitro, in compliance with the different
avidity of T-cell-receptor for specific MHC-peptide com-
plex [23]. We speculated that the 5 μg/ml peptides preferred
inducing a immune response mimicking the in vivo
condition.
In summary, this is the first report concerning the
analysis of T cell immunity against S-Ag by ELIspot
assay wherein the S-Ag Th1 cell epitope response is
measured in one uveitis entity. The peptides recognition
pattern varied between BD patients with a mild reactive
intensity. The responses to the dominant peptides and a
possible shift reactivity pattern should be verified in
more BD patients.
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